VivoSim Expands Asia-Pacific Footprint with New Distributor Deals in Korea and China
Event summary
- VivoSim Labs signed JCBio as distributor in Korea and Tekon Biotech in China for its NAMKind™ toxicology services.
- NAMKind™ services focus on liver and small intestine toxicology with a targeted 30-day turnaround time per compound.
- China's in-vitro toxicology testing market is projected to grow from $1.05B in 2023 to $2.26B by 2030.
- Drug-Induced Liver Injury (DILI) incidence in China is estimated at 23.80 per 100,000 people, higher than in Western populations.
The big picture
VivoSim’s expansion into Korea and China comes as global demand for human-relevant toxicology services accelerates. The company’s NAMKind™ services align with regulatory shifts toward non-animal testing methods, addressing critical needs in high-impact organs like liver and gastrointestinal tissues. This strategic move positions VivoSim to capitalize on the growing R&D investment and evolving regulatory standards in the Asia-Pacific region.
What we're watching
- Regulatory Alignment
- How Korea’s MFDS and U.S. FDA momentum on NAM adoption will affect VivoSim’s market penetration in Asia-Pacific.
- Market Growth
- The pace at which China's in-vitro toxicology testing market grows and how VivoSim captures this demand.
- Execution Risk
- Whether VivoSim can sustain the targeted 30-day turnaround time per study as demand scales.
Related topics